Inflammatory bowel disease appears to impact risk of Parkinson’s disease

Summary: Study provides new insights into how the immune system and inflammation play a role in the development and progression of Parkinson’s disease.

Source: IOS Press

Relatively new research findings indicating that the earliest stages of Parkinson’s disease (PD) may occur in the gut have been gaining traction in recent years. In a review published in the Journal of Parkinson’s Disease, Tomasz Brudek, PhD, evaluates evidence for the association between inflammatory bowel disease (IBD) and PD and proposes directions for future research.

“Parkinsonism is probably not just a brain disorder, but a group of diseases that may have their onset in the periphery, particularly in the gastrointestinal tract,” explained Dr. Brudek, of the Research Laboratory for Stereology and Neuroscience, and Copenhagen Center for Translational Research, Copenhagen University Hospital, Bispebjerg, and Frederiksberg Hospital, Copenhagen, Denmark. “Taken together, all data, including human, animal, and microbiome studies, suggest quite strongly that individuals with an increased tendency for peripheral inflammation have a higher risk to acquire PD. Given the potentially critical role of gut pathology in the pathogenesis of PD, there is reason to suspect that IBD may impact PD risk.”

This review explores and discusses the latest knowledge about links between IBD and PD and presents evidence from animal studies that peripheral immune system alterations may play a role in PD, which has the potential for new therapeutic strategies. It shows how our understanding and appreciation of the importance of the so-called gut-brain axis, the connection between gut and the brain in PD, has grown rapidly in recent years. It also provides important new insights into ways in which the immune system and inflammation can play a role in PD.

The inflammatory processes that occur in some patients with PD have naturally led to discussion of an association between IBD and PD since the two share some basic characteristics. IBD is currently considered an inappropriate immune response to the microbiota in the intestines, characterized by chronic pro-inflammatory immune activity, a trait now also suggested to be a fundamental element of neurodegenerative disorders. Highlighting the relevance of the immune system, large genome-wide association studies (GWAS) and pathway analyses based on 138,511 individuals of European ancestry identified 17 shared loci between PD and seven autoimmune diseases including celiac disease, rheumatoid arthritis, type 1 diabetes, multiple sclerosis, psoriasis, ulcerative colitis and Crohn’s disease.

Many epidemiological and genetic studies have found that there seems to be an increased risk of developing PD among people with IBD. The association between IBD and PD may simply be that IBD is just one type of intestinal inflammation, so it is not IBD specifically that increases the PD risk but perhaps intestinal or peripheral inflammation in a broader sense.

“Inflammation of the gut is only one of many symptoms on the list of changes in the gut and is associated with neural structures in PD patients. Thus, IBD might be just one of many sources of intestinal inflammation,” said Dr. Brudek, who is quick to point out that, “while IBD patients are more likely to get PD, the risk is still very small. For a given IBD patient, the probability of not getting the diagnosis is 95%-97%.”

This is a diagram of the gut
This review explores and discusses the latest knowledge about links between IBD and PD and presents evidence from animal studies that peripheral immune system alterations may play a role in PD, which has the potential for new therapeutic strategies. The image is in the public domain.

Looking forward, Dr Brudek noted that:

  • Identification of risk factors associated with prodromal phases of PD may allow for early intervention studies that could modify or slow down disease progress.
  • More biomarker and observational studies are needed to identify patients at risk to develop PD in order to start early therapy interventions.
  • Future pharmacological therapies aiming at slowing or stopping PD progression should not only target patients well into the course of the disease, but also be administered to patients in the very early phases of the disease or at risk for developing PD.
  • Clinicians should be aware of early Parkinsonian symptoms in IBD patients but also in patients with chronic inflammatory disorders.

“We should direct our focus on the immune system in all Parkinsonian disorders, and further investigate the role of systemic inflammation and the immune system as such in these neurological diseases. A clear knowledge of the mechanisms implicated in gut/immune/nervous communication could help improve the prognostic and therapeutic tools leading to better quality of life for patients, reducing the exacerbation of PD symptoms, and delaying the progression of the disease,” he concluded.

PD is a slowly progressive disorder that affects movement, muscle control and balance. It is the second most common age-related neurodegenerative disorder affecting about 3% of the population by the age of 65 and up to 5% of individuals over 85 years of age. During the 20th century, PD was thought to be primarily a brain disorder, however, research has shown that it may actually begin in the enteric nervous system, the part of the autonomic nervous system that controls the gastrointestinal organs.

About this neuroscience research article

Source:
IOS Press
Media Contacts:
Diana Murray – IOS Press
Image Source:
The image is in the public domain.

Original Research: Open access
“Inflammatory Bowel Diseases and Parkinson’s Disease”. Tomasz Brudek.
Journal of Parkinson’s Disease doi:10.3233/JPD-191729.

Abstract

Inflammatory Bowel Diseases and Parkinson’s Disease

The etiology of Parkinson’s disease (PD) is multifactorial, with genetics, aging, and environmental agents all a part of the PD pathogenesis. Widespread aggregation of the α-synuclein protein in the form of Lewy bodies and Lewy neurites, and degeneration of substantia nigra dopamine neurons are the pathological hallmarks of PD. Inflammatory responses manifested by glial reactions, T cell infiltration, and increased expression of inflammatory cytokines, as well as other toxic mediators derived from activated glial cells, are currently recognized as prominent features of PD. Experimental, clinical and epidemiological data suggest that intestinal inflammation contributes to the pathogenesis of PD, and the increasing number of studies suggests that the condition may start in the gastrointestinal system years before any motor symptoms develop. Patients with inflammatory bowel disease (IBD) have a higher risk of developing PD compared with non-IBD individuals. Gene association study has found a genetic link between IBD and PD, and an evidence from animal studies suggests that gut inflammation, similar to that observed in IBD, may induce loss of dopaminergic neurons. Based on preclinical models of PD, it is suggested that the enteric microbiome changes early in PD, and gut infections trigger α-synuclein release and aggregation. In this paper, the possible link between IBD and PD is reviewed based on the available literature. Given the potentially critical role of gastrointestinal pathology in PD pathogenesis, there is reason to suspect that IBD or its treatments may impact PD risk. Thus, clinicians should be aware of PD symptoms in IBD patients.

Feel free to share this Neurology News.
Join our Newsletter
I agree to have my personal information transferred to AWeber for Neuroscience Newsletter ( more information )
Sign up to receive the latest neuroscience headlines and summaries sent to your email daily from NeuroscienceNews.com
We hate spam and only use your email to contact you about newsletters. We do not sell email addresses. You can cancel your subscription any time.